Aqua Gen and Center for Integrative Genomics (CIGENE) Collaborate With Affymetrix on a Salmon Genoty
Aqua Gen and Center for Integrative Genomics (CIGENE) Collaborate With Affymetrix on a Salmon Genotyping Array to Achieve the World's First High-Density View of the Marker Patterns in the Atlantic Salmon
ÅS, Norway & SANTA CLARA, Calif.--(BUSINESS WIRE)-- Aqua Gen, a member of the Erich Wesjohann (EW) Group GmBH and Center for Integrative Genomics (CIGENE) at the Norwegian University of Life Sciences (UMB) in collaboration with Affymetrix, Inc. (NAS: AFFX) announced today that they are the first to genotype more than 900,000 markers per sample from the Atlantic salmon (Salmo salar), thereby achieving the capability to implement genomic selection and improve their salmon breeding program at Aqua Gen.
Aqua Gen, a leader in selective breeding, manages a large scale selective breeding program for Atlantic salmon, a major contributor to the world's aquaculture production. Aqua Gen has also been pioneering the use of marker-assisted selection in aquaculture breeding through their highly successful QTL-innOva products. CIGENE, located at the Norwegian University of Life Sciences, maintains research programs that contribute to the understanding of the biology of aquaculture and plant production, focusing in particular on the genetics of complex traits of economic and ecological significance. Aqua Gen and CIGENE partnered with Affymetrix to develop the salmon genotyping screening array which consists of 923,627 SNP (Single Nucleotide Polymorphism) markers and includes both diploid and tetraploid sequence variants. The goal of the ongoing study is to identify relevant and polymorphic high resolution markers that can be used downstream for marker trait association studies, genomic selection programs, as well as for a wide variety of applications in genetics and ecology.
"We are thrilled to have access to this first of its kind and groundbreaking marker map of the Atlantic salmon in such a short time," said Dr. Nina Santi, Director, Research and Development at Aqua Gen. "Aqua Gen is always looking for new technologies that can assist in the development of genetic material to meet the increasing demand for cost-effective and sustainable seafood production. This high-density SNP array gives us entirely new possibilities for improving the disease resistance and robustness of farmed Atlantic salmon. In particular, we are enthusiastic about the prospects of implementing so-called genomic selection in our breeding program. This array will also facilitate the identification of causal genetic variants underlying complex traits, thus contributing greatly to our understanding of salmonid biology."
"Development of SNP arrays and automated genotyping in Atlantic salmon is complicated by the autotetraploid whole genome duplication that occurred in the common ancestor of extant salmonids," said Dr. Sigbjørn Lien, Professor and Assistant Director, Norwegian University of Life Sciences (UMB) and Centre for Integrative Genetics (CIGENE). "The unparalleled design support and expertise from Affymetrix' team of bioinformatics scientists helped tremendously to cope with these obstacles."
"We are very pleased to partner with Aqua Gen and CIGENE and offer them our expertise in automated genotyping using the Axiom® Genotyping Solution," said Dr. Andy Last, Executive Vice President of Genetic Analysis and Clinical Applications Business Unit at Affymetrix. "The automated genotype calling in non-diploid species offers the unique advantage of accelerating data analysis by greater than 90%, to about an hour regardless of the number of SNPs, making it easier to meet tight breeding deadlines whilst also improving accuracy."
Axiom Genotyping Solution is the only platform that provides breeders and researchers with a powerful set of genotyping tools and analysis software to cost effectively identify, validate, and screen complex genetic traits. As scientists make progress in decoding genomes of various human disease states, plant, and animals using next generation sequencing platforms, they can advance their research and commercial objectives by translating those discoveries to routine applications on the Axiom Genotyping Solution platform.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®, GeneTitan® and all other trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.
Products mentioned in this release are for research use only. Not for diagnostic procedures.
About Aqua Gen
Aqua Gen AS (Trondheim, Norway) is a selective breeding company which develops, produces and delivers genetic material to the global sea-farming industry. Through a market-oriented research and development Aqua Gen has achieved a leading position as a provider of fertilized eggs of Atlantic salmon and rainbow trout. Since the 1970's when collection of these fish species began, a continual research and development program has been carried on in cooperation with commercial operators and research institutions. By focusing on genetic traits related to health, animal welfare, growth and quality, Aqua Gen contributes an important component of a sustainable and profitable aquaculture industry.
The Centre for Integrative Genetics (CIGENE) was formally established in 2003 at the Norwegian University of Life Sciences at campus Aas 30 km southeast of Oslo. Over the last decade, CIGENE has become Norway's foremost SNP genotyping facility and has gained comprehensive experience in analyzing sequencing data and developing SNP genotyping resources in a wide range of species. CIGENE has been involved in large-scale sequencing projects since 2007 and various bioinformatics pipelines have been developed, with focus on de novo assembly (such as the Atlantic salmon genome) and DNA marker development.
Affymetrix technologies are used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, and Singapore. eBioscience is headquartered in San Diego, California and has manufacturing facilities in San Diego and Vienna, Austria. Including eBioscience, the Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
To learn more about Axiom® Genotyping Solutions, please visit www.affymetrix.com/agrigenotyping for applications in agrigenomics.
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2011, and other Securities and Exchange Commission reports for subsequent quarterly periods.
Mindy Lee-Olsen, + 1 408-731-5523
Vice President, Marketing Services
Doug Farrell, +1 408-731-5285
Vice President, Investor Relations
Aqua Gen AS
Nina Santi, + 47 411 48 138
Director, Research and Development
KEYWORDS: United States Europe North America Norway California
The article Aqua Gen and Center for Integrative Genomics (CIGENE) Collaborate With Affymetrix on a Salmon Genotyping Array to Achieve the World's First High-Density View of the Marker Patterns in the Atlantic Salmon originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.